These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33558294)

  • 21. Pharmacokinetics of an elevated dosage of micafungin in premature neonates.
    Smith PB; Walsh TJ; Hope W; Arrieta A; Takada A; Kovanda LL; Kearns GL; Kaufman D; Sawamoto T; Buell DN; Benjamin DK
    Pediatr Infect Dis J; 2009 May; 28(5):412-5. PubMed ID: 19319022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
    Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
    Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Hope WW; Walsh TJ
    Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials.
    Kovanda LL; Walsh TJ; Benjamin DK; Arrieta A; Kaufman DA; Smith PB; Manzoni P; Desai AV; Kaibara A; Bonate PL; Hope WW
    Pediatr Infect Dis J; 2018 Jun; 37(6):580-585. PubMed ID: 29762386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
    Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
    Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.
    Hope WW; Kaibara A; Roy M; Arrieta A; Azie N; Kovanda LL; Benjamin DK
    Antimicrob Agents Chemother; 2015 Feb; 59(2):905-13. PubMed ID: 25421470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.
    Undre NA; Stevenson P; Freire A; Arrieta A
    Pediatr Infect Dis J; 2012 Jun; 31(6):630-2. PubMed ID: 22301478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Why might micafungin be the drug of choice in pediatric patients?].
    Ramos Amador JT; Prieto Tato L; Guillén Martín S
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.
    Manzoni P; Wu C; Tweddle L; Roilides E
    Pediatr Infect Dis J; 2014 Nov; 33(11):e291-8. PubMed ID: 24892849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
    Cross SA; Scott LJ
    Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Regulatory Review Approach for Evaluation of Micafungin for Treatment of Neonatal Candidiasis.
    Taormina G; Gopinath R; Moore J; Yasinskaya Y; Colangelo P; Reynolds K; Nambiar S
    Clin Infect Dis; 2021 Dec; 73(12):2335-2340. PubMed ID: 33458754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients.
    Scott LJ
    Paediatr Drugs; 2017 Feb; 19(1):81-90. PubMed ID: 28083856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
    Timsit JF; Azoulay E; Schwebel C; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Argaud L; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Maubon D; Jullien V; Wolff M;
    JAMA; 2016 Oct; 316(15):1555-1564. PubMed ID: 27706483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.
    Heresi GP; Gerstmann DR; Reed MD; van den Anker JN; Blumer JL; Kovanda L; Keirns JJ; Buell DN; Kearns GL
    Pediatr Infect Dis J; 2006 Dec; 25(12):1110-5. PubMed ID: 17133155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Micafungin in invasive candidiasis among oncohematological patients].
    Jarque I; Angel Sanz M
    Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Micafungin for the treatment of neonatal invasive candidiasis].
    Infante-López ME; Rojo-Conejo P
    Rev Iberoam Micol; 2009 Mar; 26(1):56-61. PubMed ID: 19463278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.
    Lempers VJ; Schouten JA; Hunfeld NG; Colbers A; van Leeuwen HJ; Burger DM; Verweij PE; Pickkers P; Brüggemann RJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4403-9. PubMed ID: 25963988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of a Quantitative PCR-Based Assay and Beta-d-Glucan Detection for Diagnosis of Invasive Candidiasis in Very-Low-Birth-Weight Preterm Neonatal Patients (CANDINEO Study).
    Ramos JT; Villar S; Bouza E; Bergon-Sendin E; Perez Rivilla A; Collados CT; Andreu M; Reyes CS; Campos-Herrero MI; de Heredia JL; Herrera MCL; Alonso PA; Pallás-Alonso CR; Cuenca-Estrella M;
    J Clin Microbiol; 2017 Sep; 55(9):2752-2764. PubMed ID: 28659321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.